Analyst Price Targets — BNTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:55 pm | Terence Flynn | Morgan Stanley | $126.00 | $93.38 | TheFly | BioNTech price target raised to $126 from $125 at Morgan Stanley |
| March 11, 2026 1:15 pm | Evan David Seigerman | BMO Capital | $128.00 | $90.52 | StreetInsider | BioNTech (BNTX) PT Lowered to $128 at BMO Capital |
| March 10, 2026 7:41 pm | Akash Tewari | Jefferies | $138.00 | $83.89 | StreetInsider | BioNTech (BNTX) PT Lowered to $138 at Jefferies |
| March 10, 2026 6:28 pm | Asthika Goonewardene | Truist Financial | $155.00 | $83.89 | StreetInsider | Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes |
| March 10, 2026 4:29 pm | — | Morgan Stanley | $128.00 | $83.89 | StreetInsider | BioNTech (BNTX) PT Lowered to $128 at BofA Securities |
| February 2, 2026 11:03 am | — | Leerink Partners | $113.00 | $113.75 | TheFly | BioNTech downgraded to Market Perform from Outperform at Leerink |
| January 16, 2026 11:49 am | — | Goldman Sachs | $142.00 | $106.07 | TheFly | BioNTech upgraded to Buy at Goldman Sachs on cancer potential |
| December 11, 2025 5:03 pm | Harry Gillis | Berenberg Bank | $155.00 | $95.68 | TheFly | BioNTech price target raised to $155 from $150 at Berenberg |
| December 11, 2025 11:43 am | Raghuram Selvaraju | H.C. Wainwright | $140.00 | $96.91 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX) |
| November 3, 2025 7:21 pm | — | Morgan Stanley | $134.00 | $103.96 | TheFly | BioNTech price target raised to $134 from $131 at Morgan Stanley |
Latest News for BNTX
Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.
Freestone Capital Holdings LLC acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ: BNTX) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,914 shares of the company's stock, valued at approximately $753,000. A number of other hedge
BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data.
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.